Daptomycin MIP: Uses, Dosage & Side Effects
A cyclic lipopeptide antibiotic for serious Gram-positive bacterial infections, including complicated skin infections, bacteraemia, and right-sided infective endocarditis
Daptomycin MIP is a cyclic lipopeptide antibiotic used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Daptomycin works by binding to bacterial cell membranes in a calcium-dependent manner, causing rapid depolarization and cell death without cell wall lysis. It is approved for complicated skin and soft tissue infections (cSSTI) in adults and children aged 1 year and older, Staphylococcus aureus bacteraemia (bloodstream infection) in adults and children, and right-sided infective endocarditis due to S. aureus in adults. Daptomycin MIP is administered intravenously in a hospital or supervised healthcare setting and requires a prescription.
Quick Facts: Daptomycin MIP
Key Takeaways
- Daptomycin MIP is a cyclic lipopeptide antibiotic with a unique mechanism of action: it binds to Gram-positive bacterial cell membranes, causing rapid depolarization and cell death, making it effective against multi-drug resistant organisms including MRSA and vancomycin-resistant enterococci (VRE).
- It is approved for complicated skin and soft tissue infections (cSSTI), Staphylococcus aureus bacteraemia, and right-sided infective endocarditis—but must never be used to treat pneumonia because pulmonary surfactant inactivates the drug.
- Creatine phosphokinase (CPK) levels must be monitored at least weekly during treatment because daptomycin can cause skeletal muscle toxicity, including myopathy and, rarely, rhabdomyolysis.
- Patients taking HMG-CoA reductase inhibitors (statins) concurrently should have their statin therapy temporarily suspended or have CPK monitored more frequently, as both drug classes can elevate CPK and increase the risk of muscle injury.
- Daptomycin is administered intravenously, either as a 30-minute infusion or a 2-minute injection, and dosing is weight-based with adjustments required for patients with severe renal impairment (creatinine clearance <30 mL/min).
What Is Daptomycin MIP and What Is It Used For?
Daptomycin MIP contains the active substance daptomycin, a naturally derived cyclic lipopeptide antibiotic originally isolated from Streptomyces roseosporus. It belongs to a unique class of antibacterial agents and has a mechanism of action that is distinct from all other currently available antibiotics. This novel mechanism makes daptomycin particularly valuable in the treatment of serious infections caused by multi-drug resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), which pose significant challenges in both hospital and community settings worldwide.
Daptomycin exerts its bactericidal effect by binding to bacterial cell membranes in a calcium-dependent process. The lipophilic tail of the daptomycin molecule inserts into the bacterial cytoplasmic membrane, forming oligomeric channels that cause rapid depolarization of the membrane potential. This depolarization leads to an efflux of potassium ions, disruption of the electrochemical gradient, and inhibition of essential cellular processes including protein synthesis, DNA replication, and RNA transcription. Unlike beta-lactam antibiotics, daptomycin achieves bacterial killing without causing cell wall lysis, which may help reduce the inflammatory response triggered by the release of bacterial cell wall fragments. The rapid bactericidal activity of daptomycin, typically demonstrable within hours of exposure, is concentration-dependent, meaning higher peak concentrations produce more rapid and more complete bacterial killing.
Daptomycin is effective exclusively against Gram-positive bacteria. Gram-negative organisms are inherently resistant because their outer membrane acts as a barrier that prevents daptomycin from reaching the cytoplasmic membrane where it exerts its action. The spectrum of activity of daptomycin encompasses a wide range of clinically important Gram-positive pathogens, including Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains), coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (including vancomycin-resistant strains), and Corynebacterium species.
Daptomycin MIP is approved by the European Medicines Agency (EMA) for the following indications:
- Complicated skin and soft tissue infections (cSSTI) in adults: Daptomycin is indicated for the treatment of cSSTI at a dose of 4 mg/kg administered once every 24 hours. Complicated skin infections include deep soft tissue infections, surgical wound infections, major abscesses, and infected ulcers or burns requiring intravenous antibiotic therapy. Clinical trials demonstrated non-inferiority of daptomycin compared with vancomycin or semi-synthetic penicillins for this indication.
- Complicated skin and soft tissue infections (cSSTI) in paediatric patients (1–17 years): Daptomycin is approved for cSSTI in children aged 1 year and older, with weight-based and age-adjusted dosing to achieve comparable drug exposures to those observed in adults.
- Staphylococcus aureus bacteraemia (SAB) in adults: Daptomycin is indicated for the treatment of S. aureus bloodstream infections at a dose of 6 mg/kg once every 24 hours. This includes both methicillin-susceptible and methicillin-resistant strains. Treatment duration is guided by the clinical response and should be continued for a minimum of 2–6 weeks as determined by the treating physician.
- Right-sided infective endocarditis (RIE) due to S. aureus in adults: Daptomycin is approved for right-sided infective endocarditis caused by S. aureus at a dose of 6 mg/kg. This represents a significant treatment option, particularly for patients with MRSA endocarditis, where therapeutic alternatives are limited.
- S. aureus bacteraemia in paediatric patients (1–17 years): Daptomycin can be used for bloodstream infections caused by S. aureus in children, with appropriate age-adjusted dosing.
Daptomycin must not be used to treat pneumonia or any pulmonary infection. Daptomycin is inactivated by pulmonary surfactant, a natural substance in the lungs that reduces surface tension. In a clinical trial comparing daptomycin to ceftriaxone for community-acquired pneumonia (CAP), daptomycin failed to demonstrate non-inferiority, confirming its ineffectiveness for lung infections. If you have pneumonia, your doctor will prescribe a different antibiotic.
Antimicrobial resistance is one of the most pressing global health threats identified by the World Health Organization (WHO). MRSA alone causes tens of thousands of deaths annually worldwide. Daptomycin’s unique mechanism of action means it remains effective against many bacteria that have developed resistance to older antibiotics, including vancomycin-intermediate S. aureus (VISA) strains. However, responsible use and antimicrobial stewardship remain essential to preserve the effectiveness of daptomycin for patients who need it most.
What Should You Know Before Taking Daptomycin MIP?
Before your doctor prescribes daptomycin, a thorough assessment of your medical history and current medications is essential. Daptomycin is a powerful antibiotic reserved for serious infections, and several important factors must be considered to ensure safe and effective treatment. Your healthcare team will evaluate your kidney function, check baseline creatine phosphokinase (CPK) levels, review all medications you are currently taking, and assess your overall clinical status to determine whether daptomycin is the most appropriate choice for your specific infection.
Contraindications
Daptomycin MIP must not be used if you have a known hypersensitivity (allergy) to daptomycin or to any of the excipients contained in the product. Allergic reactions to daptomycin can range from mild skin rashes to serious anaphylactic reactions. If you have previously experienced an allergic reaction to daptomycin or a product containing daptomycin, you must inform your doctor before treatment is considered.
Warnings and Precautions
Several important warnings and precautions apply to daptomycin therapy. Your doctor should be informed about all of the following conditions and circumstances before you begin treatment:
- Kidney problems: If you have impaired kidney function (particularly if your creatinine clearance is less than 30 mL/min), your doctor will need to adjust the dosing interval. In patients with severe renal impairment, daptomycin is administered once every 48 hours instead of once every 24 hours. Kidney function should be monitored regularly throughout treatment, especially in patients with pre-existing renal impairment or those receiving concomitant nephrotoxic agents.
- Muscle problems (myopathy/rhabdomyolysis): Daptomycin can cause skeletal muscle toxicity manifesting as muscle pain, tenderness, weakness, or elevated CPK levels. Rhabdomyolysis (severe muscle breakdown) has been reported rarely. CPK must be measured before starting therapy and at least once weekly during treatment. If CPK rises above 5 times the upper limit of normal (ULN) with muscle symptoms, or above 10 times ULN without symptoms, daptomycin should be discontinued. Patients with pre-existing myopathy, high baseline CPK, or those taking other drugs that can cause myopathy (especially statins) are at increased risk.
- Peripheral neuropathy: Cases of peripheral neuropathy have been reported during daptomycin treatment. If you experience numbness, tingling, or weakness in your extremities, inform your doctor promptly. Neurological examination should be performed and discontinuation of daptomycin considered if clinically significant neuropathy develops.
- Eosinophilic pneumonia: Rare cases of eosinophilic pneumonia have been reported in patients receiving daptomycin. Symptoms include dyspnoea (difficulty breathing), fever, and diffuse pulmonary infiltrates on chest imaging. If eosinophilic pneumonia is suspected, daptomycin should be discontinued and treatment with systemic corticosteroids considered. Most cases resolved after daptomycin was stopped.
- Superinfection: As with all antibiotics, the use of daptomycin may promote overgrowth of non-susceptible organisms, including Gram-negative bacteria and fungi. If superinfection occurs during treatment, appropriate measures should be taken. Clostridioides difficile-associated diarrhoea (CDAD) has been reported with nearly all antibacterial agents. If diarrhoea develops during or after daptomycin treatment, this possibility should be considered.
- Interference with coagulation tests: Daptomycin can interfere with certain laboratory coagulation tests, particularly those using recombinant thromboplastin reagents. This can result in a falsely elevated prothrombin time (PT) and elevated International Normalized Ratio (INR). If unexpectedly high PT/INR values are obtained in a patient receiving daptomycin, the test should be repeated using a different reagent or an alternative method to assess coagulation status.
Pregnancy and Breastfeeding
There are limited data on the use of daptomycin during pregnancy. Animal reproductive studies have not demonstrated direct harmful effects on embryo-foetal development, parturition, or postnatal growth. However, as a precautionary measure, daptomycin should not be used during pregnancy unless the potential clinical benefit clearly justifies the potential risk to the foetus. Your doctor will carefully weigh the severity of your infection and the availability of alternative treatments before prescribing daptomycin during pregnancy.
It is not known whether daptomycin is excreted in human breast milk. Because many drugs are excreted in breast milk and because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue daptomycin therapy, taking into account the importance of the drug to the mother. If daptomycin is deemed essential, breastfeeding should be stopped for the duration of treatment.
Driving and Using Machines
No studies on the effects of daptomycin on the ability to drive or use machines have been conducted. Based on the known pharmacological profile and reported adverse reactions (including dizziness and headache), daptomycin may have a minor influence on the ability to drive and use machines. Patients who experience dizziness or other neurological symptoms should avoid driving or operating heavy machinery until these effects resolve.
Before treatment with daptomycin, always tell your doctor if you: have kidney problems, have ever had muscle problems or elevated CPK levels, are taking statins or other cholesterol-lowering medications, are taking any other medications (including over-the-counter medicines and supplements), are pregnant, planning to become pregnant, or breastfeeding, or have a history of allergic reactions to antibiotics.
How Does Daptomycin MIP Interact with Other Drugs?
Formal drug interaction studies with daptomycin have been limited, but available data and clinical experience provide important guidance on potential interactions. Daptomycin is neither a substrate nor an inhibitor of cytochrome P450 (CYP450) enzymes, which is the main metabolic pathway for many medications. This means that daptomycin is unlikely to alter the plasma concentrations of drugs metabolised by CYP450 enzymes, and CYP450 inhibitors or inducers are unlikely to affect daptomycin levels. Nevertheless, certain interactions are clinically important and warrant careful consideration.
The pharmacokinetic profile of daptomycin is well characterised. Daptomycin is primarily eliminated by renal excretion, with approximately 78% of the administered dose recovered in urine as unchanged drug. It is approximately 90–93% bound to plasma proteins, primarily albumin. The terminal elimination half-life is approximately 8–9 hours in patients with normal renal function, allowing once-daily dosing.
Major Interactions
| Drug/Class | Interaction Effect | Recommendation |
|---|---|---|
| HMG-CoA Reductase Inhibitors (Statins) | Both daptomycin and statins can cause CPK elevation and myopathy. Concurrent use may increase the risk of skeletal muscle toxicity, including rhabdomyolysis. | Temporarily discontinue statin therapy during daptomycin treatment. If statin cannot be stopped, monitor CPK more frequently than weekly. Immediately report muscle pain, tenderness, or weakness. |
| Tobramycin | Co-administration of daptomycin with tobramycin increased the AUC of daptomycin by approximately 12.7% in a pharmacokinetic study. Both agents are nephrotoxic and may increase the risk of kidney injury. | Use caution with concurrent aminoglycosides. Monitor renal function closely. Dose adjustments may be needed based on kidney function. |
| Warfarin | Daptomycin can cause falsely elevated prothrombin time (PT) and INR values with certain laboratory reagents. True pharmacokinetic interaction is not significant. | If PT/INR results are unexpectedly high, repeat the test using a different reagent. Monitor anticoagulation closely during concurrent use. |
Minor Interactions
| Drug/Class | Interaction Effect | Recommendation |
|---|---|---|
| Ciclosporin | No clinically relevant pharmacokinetic interaction observed in studies. Neither daptomycin nor ciclosporin exposures were significantly altered. | No dose adjustment required for either drug. Standard monitoring of ciclosporin levels should continue. |
| Probenecid | Probenecid did not significantly alter the pharmacokinetics of daptomycin in clinical studies. | No dose adjustment necessary. Routine monitoring is sufficient. |
| Aztreonam | No clinically significant pharmacokinetic interaction demonstrated. Daptomycin does not have activity against Gram-negative bacteria; aztreonam may be added for Gram-negative coverage. | Combination may be appropriate when mixed Gram-positive and Gram-negative coverage is needed. No dose adjustment required. |
| Other nephrotoxic agents | Concurrent use of nephrotoxic agents (e.g., NSAIDs, ACE inhibitors, vancomycin, amphotericin B) may increase the risk of renal impairment, which can secondarily affect daptomycin clearance. | Monitor renal function more frequently. Adjust daptomycin dosing interval if creatinine clearance falls below 30 mL/min. |
A significant advantage of daptomycin from a drug interaction perspective is that it is not metabolised by, and does not inhibit or induce, cytochrome P450 enzymes. This means it has a lower potential for pharmacokinetic drug-drug interactions than many other antibiotics. However, pharmacodynamic interactions (where two drugs produce overlapping effects, such as muscle toxicity with statins) remain important to consider.
What Is the Correct Dosage of Daptomycin MIP?
Daptomycin MIP is always administered under the supervision of a healthcare professional experienced in the management of infectious diseases. The dose is calculated based on the patient’s body weight and the type of infection being treated. It is critical that the correct dose and frequency are maintained throughout the treatment course to ensure optimal drug exposure and to minimise the risk of treatment failure or the development of resistance.
Adults
Complicated Skin and Soft Tissue Infections (cSSTI)
Dose: 4 mg/kg administered once every 24 hours by intravenous infusion over 30 minutes or by intravenous injection over 2 minutes.
Duration: 7–14 days or until the infection has resolved. Treatment duration should be guided by clinical response, and therapy should not be discontinued prematurely even if symptoms improve before the full course is completed.
S. aureus Bacteraemia & Right-Sided Infective Endocarditis
Dose: 6 mg/kg administered once every 24 hours by intravenous infusion over 30 minutes or by intravenous injection over 2 minutes.
Duration: Minimum 2–6 weeks. The treating physician will determine the appropriate duration based on the clinical response, the site and severity of infection, microbiological findings, and the individual patient’s risk factors. Infective endocarditis typically requires prolonged treatment courses.
Children (1–17 Years)
Paediatric dosing is age-adjusted to achieve drug exposures comparable to those observed in adults. The following doses are recommended:
| Age Group | Indication | Dose | Route & Duration |
|---|---|---|---|
| 12–17 years | cSSTI | 5 mg/kg once every 24 hours | IV infusion over 30 min or IV injection over 2 min; up to 14 days |
| 7–11 years | cSSTI | 7 mg/kg once every 24 hours | IV infusion over 30 min; up to 14 days |
| 2–6 years | cSSTI | 9 mg/kg once every 24 hours | IV infusion over 60 min; up to 14 days |
| 1 to <2 years | cSSTI | 12 mg/kg once every 24 hours | IV infusion over 60 min; up to 14 days |
| 12–17 years | S. aureus bacteraemia | 7 mg/kg once every 24 hours | IV infusion over 30 min or IV injection over 2 min; up to 42 days |
| 7–11 years | S. aureus bacteraemia | 9 mg/kg once every 24 hours | IV infusion over 30 min; up to 42 days |
| 1–6 years | S. aureus bacteraemia | 12 mg/kg once every 24 hours | IV infusion over 60 min; up to 42 days |
Elderly
No dosage adjustment is necessary for elderly patients based on age alone. However, elderly patients are more likely to have reduced renal function, and dose adjustment based on creatinine clearance should be considered. CPK monitoring is particularly important in older adults, as they may be more susceptible to myopathy and are more likely to be taking concomitant medications that increase this risk, such as statins.
Renal Impairment
Daptomycin is primarily excreted by the kidneys. In patients with severe renal impairment (creatinine clearance <30 mL/min), including those receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), the dosing interval must be extended:
Dose Adjustment for Renal Impairment
CrCl ≥30 mL/min: No adjustment required. Standard dosing every 24 hours.
CrCl <30 mL/min (including dialysis patients): Same dose (4 mg/kg for cSSTI or 6 mg/kg for bacteraemia/endocarditis) administered once every 48 hours. On haemodialysis days, daptomycin should be administered after dialysis is completed.
Missed Dose
Since daptomycin is administered in a hospital or clinical setting under supervision, missed doses are uncommon. If a dose is inadvertently delayed, it should be administered as soon as possible, and the subsequent dose schedule adjusted accordingly. The dose should not be doubled to compensate for a missed dose. Your healthcare team will ensure that the dosing schedule is maintained throughout your treatment course.
Overdose
There is limited clinical experience with daptomycin overdose. In the event of overdose, supportive care is recommended. Daptomycin is slowly cleared by haemodialysis (approximately 15% of the administered dose over 4 hours) and by peritoneal dialysis (approximately 11% over 48 hours). High-flux dialysis membranes may increase the rate of clearance. The most likely manifestation of overdose would be exaggerated adverse effects, particularly CPK elevation and myopathy. Close monitoring of CPK levels and renal function is advised, with supportive treatment as clinically indicated.
Daptomycin MIP 350 mg powder must be reconstituted and then further diluted in 0.9% sodium chloride (50 mL) for intravenous infusion over 30 minutes, or administered as a slow intravenous injection over 2 minutes after reconstitution. The 2-minute injection option can be more convenient and may reduce infusion-related reactions. Daptomycin must not be mixed with glucose (dextrose)-containing solutions or with other medicinal products via the same intravenous line.
What Are the Side Effects of Daptomycin MIP?
Like all medicines, Daptomycin MIP can cause side effects, although not everybody gets them. The side effects listed below are based on data from clinical trials and post-marketing surveillance. The frequency of side effects is categorised according to international convention: very common (affects more than 1 in 10 people), common (up to 1 in 10), uncommon (up to 1 in 100), rare (up to 1 in 1,000), and not known (cannot be estimated from available data).
It is important to understand that the overall safety profile of daptomycin has been well established through extensive clinical use and regulatory review. Most side effects are mild to moderate in severity and resolve after treatment is completed. However, some side effects, particularly those related to muscle toxicity and hypersensitivity, require prompt medical attention. You should report any new or unusual symptoms to your healthcare team immediately.
Common
- Fungal infections (including oral and vaginal candidiasis)
- Urinary tract infections
- Anaemia (low red blood cell count)
- Anxiety, insomnia
- Dizziness, headache
- Hypertension (high blood pressure), hypotension (low blood pressure)
- Nausea, vomiting, diarrhoea, constipation, abdominal pain, flatulence
- Elevated liver enzymes (ALT, AST, alkaline phosphatase)
- Rash, pruritus (itching)
- Limb pain, elevated CPK
- Infusion site reactions
- Pyrexia (fever)
- Asthenia (weakness, fatigue)
Uncommon
- Blood disorders: thrombocythaemia (high platelet count), eosinophilia, increased INR
- Decreased appetite
- Hyperglycaemia (high blood sugar)
- Electrolyte disturbances (hypomagnesaemia, hyperkalaemia)
- Paraesthesia (tingling), taste disturbance, tremor
- Flushing, supraventricular tachycardia
- Gastrointestinal bleeding, pancreatitis, stomatitis
- Jaundice, elevated bilirubin
- Urticaria (hives)
- Myalgia (muscle pain), myositis, muscle weakness, arthralgia (joint pain)
- Renal impairment (including renal failure)
- Vaginal candidiasis
- Rigors (chills), oedema
Rare
- Rhabdomyolysis (severe muscle breakdown with potential kidney damage)
- Eosinophilic pneumonia (allergic lung inflammation)
- Peripheral neuropathy
- Myoglobinuria (muscle protein in urine)
Not Known
- Anaphylaxis (severe allergic reaction)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Angioedema (swelling of face, lips, throat)
- Acute generalised exanthematous pustulosis (AGEP)
- Clostridioides difficile-associated diarrhoea (antibiotic-associated colitis)
Contact your doctor or nurse immediately or go to the nearest emergency department if you experience: severe allergic reaction (difficulty breathing, swelling of face/throat, severe skin rash or hives), unexplained severe muscle pain, tenderness or weakness (especially with dark-coloured urine), new onset of difficulty breathing or worsening cough with fever, or severe watery or bloody diarrhoea during or after treatment.
Your doctor will order regular blood tests to check your creatine phosphokinase (CPK) levels, typically once per week during treatment. CPK is an enzyme released into the blood when muscle tissue is damaged. If your CPK levels rise significantly, your doctor may need to stop daptomycin treatment. Report any unexplained muscle pain, tenderness, cramping, or weakness to your healthcare team promptly, as these may be early signs of muscle toxicity.
How Should You Store Daptomycin MIP?
Proper storage of Daptomycin MIP is essential to maintain the stability and efficacy of the medication. Since daptomycin is administered in a hospital or clinical setting, the storage conditions are primarily the responsibility of the pharmacy and nursing staff. However, understanding the storage requirements helps ensure the medication you receive is of the highest quality.
- Unopened vials: Store below 30°C. Do not freeze. Keep the vial in the outer carton to protect from light.
- After reconstitution: Chemical and physical in-use stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours at 2–8°C (refrigerated).
- After dilution for infusion: The diluted solution (in 0.9% sodium chloride) is stable for 12 hours at 25°C or 24 hours at 2–8°C. Combined reconstitution and dilution storage time should not exceed 12 hours at 25°C or 24 hours at 2–8°C.
- Do not use this medicine after the expiry date stated on the carton and vial label. The expiry date refers to the last day of that month.
- Keep this medicine out of the sight and reach of children.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The reconstituted and diluted solution should be inspected visually for particulate matter and discolouration prior to administration. Only clear solutions without visible particles should be used. The colour of reconstituted daptomycin ranges from pale yellow to light brown. Variations in colour within this range do not affect the potency of the product.
What Does Daptomycin MIP Contain?
Daptomycin MIP is formulated as a lyophilised (freeze-dried) powder that must be reconstituted before administration. The formulation is designed to ensure stability during storage and rapid dissolution when reconstituted with the appropriate diluent.
Active Substance
Each vial contains 350 mg of daptomycin. Daptomycin is a cyclic lipopeptide antibiotic derived from the fermentation of Streptomyces roseosporus. Its molecular formula is C72H101N17O26, with a molecular weight of approximately 1,620.67 daltons. The molecule consists of a 13-amino acid cyclic peptide with a decanoyl lipid side chain, which is responsible for its membrane-binding activity.
Inactive Ingredients (Excipients)
- Sodium hydroxide (for pH adjustment)
The formulation of Daptomycin MIP is notably simple, containing only the active substance and sodium hydroxide for pH adjustment. This minimalist formulation reduces the risk of excipient-related adverse reactions and hypersensitivity.
Appearance
Daptomycin MIP is a pale yellow to light brown lyophilised powder or cake supplied in a clear glass vial. After reconstitution with 7 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, the resulting solution has a concentration of approximately 50 mg/mL. The reconstituted solution should be clear and free from visible particles. Each carton contains one single-use vial.
Manufacturer
Daptomycin MIP is manufactured and marketed by MIP Pharma GmbH. It is a generic version of the originator product Cubicin, which was originally developed by Cubist Pharmaceuticals (now part of Merck & Co.). As a generic medicine, Daptomycin MIP has been demonstrated to be bioequivalent to the reference product and has been approved through the European decentralised procedure.
Frequently Asked Questions About Daptomycin MIP
Daptomycin MIP is a cyclic lipopeptide antibiotic used to treat serious infections caused by Gram-positive bacteria. It is approved for complicated skin and soft tissue infections (cSSTI) in adults and children aged 1 year and older, Staphylococcus aureus bacteraemia (bloodstream infection) in adults and children, and right-sided infective endocarditis due to S. aureus in adults. It is particularly valuable for infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
Daptomycin is inactivated by pulmonary surfactant, a natural substance in the lungs that reduces surface tension and helps keep the air sacs (alveoli) open. Surfactant binds to daptomycin and prevents it from interacting with bacterial cell membranes, rendering it ineffective in the lung environment. A clinical trial confirmed that daptomycin was not effective for community-acquired pneumonia. Therefore, other antibiotics must be used for lung infections.
Creatine phosphokinase (CPK) levels should be measured before starting daptomycin and at least once weekly during treatment. If you are also taking statins or other medications that can affect muscles, your doctor may order CPK tests more frequently. Kidney function and liver enzymes will also be monitored regularly. If your CPK rises significantly or if you develop muscle symptoms, your doctor may decide to stop daptomycin treatment.
Yes, daptomycin is highly effective against MRSA (methicillin-resistant Staphylococcus aureus). Its mechanism of action—disrupting the bacterial cell membrane rather than targeting cell wall synthesis or protein synthesis—means it retains activity against bacteria that have developed resistance to beta-lactam antibiotics (including methicillin), vancomycin-intermediate strains, and many other antibiotic classes. Daptomycin is one of the key drugs recommended by international guidelines (IDSA, ESCMID) for the treatment of serious MRSA infections.
Daptomycin MIP is administered intravenously (into a vein) by a healthcare professional in a hospital or clinical setting. It can be given as an intravenous infusion over 30 minutes (diluted in 0.9% sodium chloride) or as a slow intravenous injection over 2 minutes (after reconstitution). The drug is given once daily, and the dose is based on your body weight and the type of infection being treated. It must not be mixed with glucose-containing solutions.
Yes, daptomycin is approved for use in children aged 1 year and older for complicated skin and soft tissue infections and Staphylococcus aureus bacteraemia. However, it is not approved for use in children under 1 year of age. Paediatric dosing is different from adult dosing and is adjusted based on the child’s age to achieve appropriate drug exposure levels. Younger children require higher mg/kg doses because they metabolise the drug more rapidly than adults. Your child’s doctor will determine the correct dose.
References
- European Medicines Agency (EMA). Daptomycin MIP – Summary of Product Characteristics. Last updated 2025. Available from: EMA Product Information.
- U.S. Food and Drug Administration (FDA). Cubicin (daptomycin for injection) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–1681. doi:10.1086/420818.
- Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665. doi:10.1056/NEJMoa053783.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis. 2011;52(3):e18–e55. doi:10.1093/cid/ciq146.
- Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81(2):79–91. doi:10.1159/000109868.
- Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26(4):759–780. doi:10.1128/CMR.00030-13.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Gudiol F, Aguado JM, Almirante B, et al. Diagnosis and treatment of bacteremia and endocarditis caused by Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015;33(9):625.e1–625.e23.
- Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Seaton RA, Loeffler J, Chaves RL. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66(4):912–919. doi:10.1093/jac/dkq528.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in infectious diseases, microbiology, and clinical pharmacology.
Medical Content
iMedic Infectious Diseases Editorial Team – specialist physicians in infectious diseases and microbiology with clinical experience in antimicrobial therapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, IDSA, and ESCMID guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, antimicrobial stewardship, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.